-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Biogen, Raises Price Target to $187

Benzinga·02/10/2026 14:43:33
Listen to the news
Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $178 to $187.